Last reviewed 2026-05-14 · How we verify

AK112 with SCRT and CapeOX

AK112 is a bispecific antibody that simultaneously engages PD-1 and LAG-3 to enhance anti-tumor immune responses, combined with chemotherapy (capecitabine and oxaliplatin) to treat solid tumors.

AK112 is a bispecific antibody that simultaneously engages PD-1 and LAG-3 to enhance anti-tumor immune responses, combined with chemotherapy (capecitabine and oxaliplatin) to treat solid tumors. Used for Advanced or metastatic solid tumors (in combination with capecitabine and oxaliplatin).

At a glance

Mechanism of action

AK112 functions as a dual checkpoint inhibitor by binding both PD-1 and LAG-3 on T cells, relieving immune suppression and promoting T-cell activation and proliferation. When combined with CapeOX chemotherapy, the regimen aims to synergistically enhance anti-tumor immunity through both checkpoint blockade and direct cytotoxic effects on cancer cells.

Approved indications

• Advanced or metastatic solid tumors (in combination with capecitabine and oxaliplatin)

Common side effects

• Fatigue
• Nausea
• Diarrhea
• Immune-related adverse events (irAEs)
• Neutropenia

Key clinical trials

• Neoadjuvant Short-Course Radiotherapy With or Without Chemotherapy and AK112 in Locally Advanced Rectal Cancer (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• AK112 with SCRT and CapeOX CI brief — competitive landscape report
• AK112 with SCRT and CapeOX updates RSS · CI watch RSS
• fan li portfolio CI